Food allergy treatment value: Child caregiver and patient perspectives.
caregivers
comparative effectiveness research
delphi technique
food allergy
food hypersensitivity
quality of life
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
26
01
2021
received:
22
12
2020
accepted:
02
02
2021
pubmed:
6
2
2021
medline:
1
9
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
Food allergy is a major health problem that significantly impacts quality of life (QoL). There is growing focus to evaluate food allergy-related QoL and treatment options' value beyond the clinical effectiveness perspective by engaging patients and caregivers. We aimed to identify and prioritize outcomes important to food allergy parents of children and patients allergic to milk, egg, and/or peanut, to guide comparative effectiveness research (CER) that focuses on evaluating food allergy treatment decisions. We conducted a modified 3-round Delphi study to identify and derive consensus on priority treatment outcomes for parents of children and adult patients with diagnosed allergies to at least one of three major allergenic foods (milk, egg, and peanut) from across the United States. Round 1 yielded 44 statements for round 2, and 39 statements reached the agreement level for round 3 ranking. Statements were organized under 4 sections: 1) food allergy problems, 2) treatment experiences, 3) important treatment outcomes, and 4) value of different treatment options. Food allergy parents and patients face several social, psychological, medical, healthcare, financial, food selection, and awareness challenges. The areas of consensus on important treatment outcomes revealed shared priority for reducing the risk of potentially fatal allergic reactions and having reliable treatments. The most valued treatment options reflect hope for permanent cure and fear of serious allergic reactions.
Sections du résumé
BACKGROUND
Food allergy is a major health problem that significantly impacts quality of life (QoL). There is growing focus to evaluate food allergy-related QoL and treatment options' value beyond the clinical effectiveness perspective by engaging patients and caregivers. We aimed to identify and prioritize outcomes important to food allergy parents of children and patients allergic to milk, egg, and/or peanut, to guide comparative effectiveness research (CER) that focuses on evaluating food allergy treatment decisions.
METHODS
We conducted a modified 3-round Delphi study to identify and derive consensus on priority treatment outcomes for parents of children and adult patients with diagnosed allergies to at least one of three major allergenic foods (milk, egg, and peanut) from across the United States.
RESULTS
Round 1 yielded 44 statements for round 2, and 39 statements reached the agreement level for round 3 ranking. Statements were organized under 4 sections: 1) food allergy problems, 2) treatment experiences, 3) important treatment outcomes, and 4) value of different treatment options.
CONCLUSION
Food allergy parents and patients face several social, psychological, medical, healthcare, financial, food selection, and awareness challenges. The areas of consensus on important treatment outcomes revealed shared priority for reducing the risk of potentially fatal allergic reactions and having reliable treatments. The most valued treatment options reflect hope for permanent cure and fear of serious allergic reactions.
Identifiants
pubmed: 33544417
doi: 10.1111/pai.13464
pmc: PMC8359212
doi:
Substances chimiques
Allergens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1038-1047Informations de copyright
© 2021 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
JAMA Pediatr. 2013 Nov;167(11):1026-31
pubmed: 24042236
JAMA Netw Open. 2019 Jan 4;2(1):e185630
pubmed: 30646188
Nat Rev Dis Primers. 2018 Jan 04;4:17098
pubmed: 29300005
Pediatr Allergy Immunol. 2021 Jul;32(5):1038-1047
pubmed: 33544417
J Allergy Clin Immunol Pract. 2015 Jan-Feb;3(1):68-75
pubmed: 25577621
Curr Opin Allergy Clin Immunol. 2020 Apr;20(2):188-193
pubmed: 31977449
J Allergy Clin Immunol. 2014 Feb;133(2):291-307; quiz 308
pubmed: 24388012
Ann Allergy Asthma Immunol. 2010 Oct;105(4):287-294
pubmed: 20934628
Aust N Z J Psychiatry. 2015 Oct;49(10):887-97
pubmed: 26296368
Curr Opin Allergy Clin Immunol. 2016 Jun;16(3):284-90
pubmed: 27070333
Ann Allergy Asthma Immunol. 2001 Feb;86(2):172-6
pubmed: 11258686
Ann Allergy Asthma Immunol. 2019 Apr;122(4):373-380.e1
pubmed: 30703439
Patient. 2019 Dec;12(6):631-638
pubmed: 31347011
Pediatr Allergy Immunol. 2014 May;25(3):236-42
pubmed: 24750570
Curr Allergy Asthma Rep. 2017 Jun;17(6):39
pubmed: 28516366
Appl Health Econ Health Policy. 2019 Apr;17(2):163-174
pubmed: 30350218
Med Care. 2010 Jun;48(6 Suppl):S7-8
pubmed: 20473202
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S116-25
pubmed: 20042231
Pediatrics. 2018 Dec;142(6):
pubmed: 30455345
J Paediatr Child Health. 2015 Jul;51(7):696-8
pubmed: 25594910
J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):363-368.e2
pubmed: 28017626
JAMA. 2014 Oct 15;312(15):1513-4
pubmed: 25167382
J Manag Care Spec Pharm. 2020 May;26(5):620-623
pubmed: 32347174
Allergy. 2010 Aug;65(8):933-45
pubmed: 20180792